InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches Immune Response Template (IRT) version 3.7.0. IRT represents a QSP platform of immune system, simultaneously, being a tool for development of models related to immune system.

Generally, IRT is based on two main components. On the one hand, it is a fully-fledged database including a wide variety of features covering the immune system. On the other hand, it comprises Navigator that provides intuitive interface to interact with IRT Database. Thus, a modeler can apply calibrated submodels exported from IRT as building blocks to simplify the model development process.

IRT is a part of InSysBio’s QSP software infrastructure being under constant upgrade. IRT v.3.7.0 gets a range of new features:

• Immunological Synapse submodels are updated. Each surface molecule now has degradation and synthesis velocities.
• Immunological Synapse schemes are updated. Now they are more convenient and clearer. New details have also been added to the schemes.
• Minor fixes have been added.

Veronika Musatova, Head of IRT development team, comments on the new version, “This update brings a meaningful improvement to the Immunological Synapse submodels. Introducing synthesis and degradation of each surface molecule, we add important biological dynamics, aligning the submodels more closely with real cellular behavior. These processes are commonly used in the development of QSP models to capture turnover and regulation mechanisms.”

To learn the full content of Immune Response Template, please visit irt.insysbio.com

To get demo access to IRT, please click “sign in” or “user account” on irt.insysbio.com

To get more information on any tool or leave your feedback, please feel free to contact us: support@insysbio.com

About InSysBio

InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com

Share